These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3886286)

  • 1. Membrane selection for renal replacement therapy: a mountain or molehill?
    Farrell PC; Odell RA
    Contrib Nephrol; 1985; 44():97-111. PubMed ID: 3886286
    [No Abstract]   [Full Text] [Related]  

  • 2. Cellulose membranes--time for a change?
    Henderson LW; Chenoweth DE
    Contrib Nephrol; 1985; 44():112-26. PubMed ID: 3872769
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of dialysis membrane on serum beta 2-microglobulin (beta 2M) in chronic haemodialysis patients.
    Farrell J; Bastani B
    Nephrol Dial Transplant; 1997 Apr; 12(4):856. PubMed ID: 9141041
    [No Abstract]   [Full Text] [Related]  

  • 4. Membrane biocompatibility: clinical significance and therapeutic implications.
    Dumler F; Levin NW
    Int J Artif Organs; 1985 Sep; 8(5):257-62. PubMed ID: 3910591
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute renal failure: role of dialysis membrane biocompatibility.
    Pascual M; Swinford RD; Tolkoff-Rubin N
    Annu Rev Med; 1997; 48():467-76. PubMed ID: 9046977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dialyzer geometry during hemodialysis with cuprophane membranes.
    Taylor JE; McLaren M; Mactier RA; Henderson IS; Stewart WK; Belch JJ
    Kidney Int; 1992 Aug; 42(2):442-7. PubMed ID: 1405328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypersensitivity reactions related to acetate dialyzate and cellulose acetate membrane.
    Caravaca F; Pizarro JL; Arrobas M; Cubero JJ; Antona JM; Sanchez E
    Nephron; 1987; 45(2):158-9. PubMed ID: 3561625
    [No Abstract]   [Full Text] [Related]  

  • 8. Leucocyte occlusion of cuprophane membranes as a cause of reduced hemodialysis efficiency.
    Dodd NJ; Parsons V; Weston MJ
    Int J Artif Organs; 1982 Jul; 5(4):275-6. PubMed ID: 7118290
    [No Abstract]   [Full Text] [Related]  

  • 9. Cuprophan membrane induces interleukin-1 activity.
    Yamagami S; Yoshihara H; Kishimoto T; Sugimura T; Niwa M; Maekawa M
    ASAIO Trans; 1986; 32(1):98-101. PubMed ID: 3490869
    [No Abstract]   [Full Text] [Related]  

  • 10. Continuous renal replacement therapy in acute renal failure: membranes for CRRT.
    Jones CH
    Artif Organs; 1998 Jan; 22(1):2-7. PubMed ID: 9456218
    [No Abstract]   [Full Text] [Related]  

  • 11. Focusing on membranes.
    von Sengbusch G; Bowry S; Vienken J
    Artif Organs; 1993 Apr; 17(4):244-53. PubMed ID: 8498904
    [No Abstract]   [Full Text] [Related]  

  • 12. The next generation of dialysis membranes--barriers or pathways?
    Streicher E; Schneider H
    Contrib Nephrol; 1985; 44():127-36. PubMed ID: 3987283
    [No Abstract]   [Full Text] [Related]  

  • 13. Biocompatibility of a new high-permeability modified cellulose membrane for haemodialysis.
    Ward RA; Schaefer RM; Falkenhagen D; Joshua MS; Heidland A; Klinkmann H; Gurland HJ
    Nephrol Dial Transplant; 1993; 8(1):47-53. PubMed ID: 8381935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biocompatible membranes in acute renal failure: prospective case-controlled study.
    Shaldon S
    Nephrol Dial Transplant; 1997 Jan; 12(1):235-6. PubMed ID: 9027814
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypersensitivity reactions to ethylene oxide: clinical experience.
    Masin G; Polenaković M; Ivanovski N; Atanasov N; Olivera S; Cakalaroski K
    Nephrol Dial Transplant; 1991; 6 Suppl 3():50-2. PubMed ID: 1775268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of leukotriene B4 by hemodialyzer membranes: a novel index of biocompatibility.
    Strasser T; Schiffl H
    Klin Wochenschr; 1991 Oct; 69(17):808-12. PubMed ID: 1662325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects of hemodialysis.
    Eknoyan G
    N Engl J Med; 1984 Oct; 311(14):915-7. PubMed ID: 6472405
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of lupus anticoagulant and anticardiolipin antibodies in haemodialysis patients.
    Phillips AO; Jones HW; Hambley H; Hillis AN; Hendry BM
    Nephron; 1993; 65(3):350-3. PubMed ID: 8289982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biocompatible dialysis membranes and oxidative stress in patients wih end-stage renal disease on maintenance haemodialysis.
    Abdel-Naeem NM; Kandell NF; El-Shamaa AA; Harba TM; Abdel-Hady AA
    J Egypt Soc Parasitol; 2005 Dec; 35(3 Suppl):1173-97. PubMed ID: 16363293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-flux hemodialysis: overcoming the tyranny of time.
    Barth RH
    Contrib Nephrol; 1993; 102():73-97. PubMed ID: 8416190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.